REL-1017 is an investigational drug.
There have been 9 clinical trials for REL-1017.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2021.
The most common disease conditions in clinical trials are Depressive Disorder, Major, Depressive Disorder, and Depression. The leading clinical trial sponsors are Relmada Therapeutics, Inc., Syneos Health, and Clinical Trial Unit Ente Ospedaliero Cantonale.
There are six hundred and thirty-six US patents protecting this investigational drug and zero international patents.